Analyst Profile

Followed by 109 followers
.
Serge Belanger

Serge Belanger

Needham
Wall Street Analyst
#7,624 out of 8,160 Wall Street Analysts
#22,908 out of 24,427 experts

Success Rate

40%
119 out of 297 transactions made a profit

Average Return

-5.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Serge Belanger's trades since 2015 and holding each position for 1 Year would result in 40.07% of your transactions generating a profit, with an average return of -5.4% per rating.

Stock Rating Distribution

936Ratings
78.42% Buy
21.58% Hold
0.00% Sell
Distribution of Serge Belanger's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Xenon Pharmaceuticals
(XENE)
Rating:Buy
Date:Nov 09, 2020 - Nov 09, 2021
Return:+211.90%
The most profitable rating made by Serge Belanger

Serge Belanger's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
DYAX
Dyax Corp
Nov 05, 2015
Hold
Downgraded
6Ratings
0.00%
Altamira Therapeutics
Aug 19, 2016
Buy
Reiterated
$5.00
(-14.90% Downside)
3Ratings
0.00%
PTXTQ
Pernix Therapeutics
Oct 03, 2016
Hold
Reiterated
4Ratings
0.00%
Evofem Biosciences
Jun 26, 2017
Hold
Reiterated
2Ratings
0.00%
SNMX
Senomyx
Jul 24, 2017
Hold
Reiterated
8Ratings
0.00%
CORI
Corium
Oct 15, 2018
Hold
Downgraded
7Ratings
0.00%
ALDR
Alder Biopharmaceuticals
Sep 16, 2019
Hold
Downgraded
2Ratings
0.00%
~DERM
Dermira
Jan 24, 2020
Hold
Downgraded
19Ratings
0.00%
AMAG
Amag Pharmaceuticals
Oct 01, 2020
Hold
Reiterated
12Ratings
0.00%
GWPH
GW Pharma
Feb 03, 2021
Hold
Downgraded
14Ratings
100%
+75.05%
List of latest recommendations made by Serge Belanger. Click to expand and see Serge Belanger's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >